Quarterly Updates26 May 2026, 01:24 pm
Aarti Pharmalabs: FY26 Revenue ₹179,755.17 Lakhs
AI Summary
Aarti Pharmalabs Ltd's Board of Directors approved the audited financial results for the quarter and financial year ended March 31, 2026. The company reported revenue from operations (net) of ₹179,755.17 lakhs for FY26. A final dividend of ₹2 per equity share was recommended. Smt. Ketki D. Visariya was re-appointed as the Cost Auditor and Manish Modi & Associates as the Internal Auditor for FY 2026-27. Mr. Sachin Patil and Mr. Rajendra Pagare were designated as Senior Management Personnel.
Key Highlights
- Audited FY26 revenue from operations (net) is ₹179,755.17 lakhs.
- Recommended final dividend of ₹2 per equity share for FY26.
- Ketki D. Visariya re-appointed as Cost Auditor for FY 2026-27.
- Manish Modi & Associates re-appointed as Internal Auditor for FY 2026-27.
- Sachin Patil and Rajendra Pagare designated as Senior Management Personnel.
Price Impact
More from AARTIPHARM